Document is current
Any future updates will be listed below
-
Authors
Ibrahim, Khalid A. http://orcid.org/0000-0003-1819-1952
Grußmayer, Kristin S. http://orcid.org/0000-0003-4515-4356
Riguet, Nathan http://orcid.org/0000-0002-5073-8084
Feletti, Lely http://orcid.org/0009-0001-4413-3396
Lashuel, Hilal A. http://orcid.org/0000-0001-7682-8320
Radenovic, Aleksandra http://orcid.org/0000-0001-8194-2785
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (NCCR)
- License Information
-
More Information
Article History
Received: 23 April 2023
Accepted: 9 November 2023
First Online: 28 November 2023
Competing interests
: H.A.L. has received funding from the industry to support research on neurodegenerative diseases, including from Merck Serono, UCB, and Abbvie. These companies had no specific role in the conceptualization, preparation, and decision to publish this work. H.A.L. is also the co-founder and Chief Scientific Officer of ND BioSciences SA, a company that develops diagnostics and treatments for neurodegenerative diseases based on platforms that reproduce the complexity and diversity of proteins implicated in neurodegenerative diseases and their pathologies. All remaining authors declare no competing interests.
